Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
These findings follow positive Phase 3 results presented earlier this year
Subscribe To Our Newsletter & Stay Updated
